Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 4B 3.68B 3.45B 6.46B 429B 6.6B 44.21B 17.12B 212B 17.09B 16.71B 736B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.13B 3.8B 3.56B 6.67B 443B 6.81B 45.66B 17.68B 219B 17.64B 17.26B 760B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
3 months+0.42%
6 months+1.68%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 5.64
Extreme 5.645
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
04-27Issuer sale

Chairman

419,487 0.1336%
04-27Issuer sale

Director

398,261 0.1268%
04-27Issuer sale

Director

310,136 0.0988%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+156.01%+18.00% 4.55B
-0.48%+8.75%-5.51%+0.91% 46.36B
+2.19%+11.71%+374.04%+613.48% 37.88B
+2.53%+13.93%+20.43%-10.71% 31.12B
+1.65%+3.61%+4.78%+56.12% 30.61B
-4.16%-4.44%+8.53%+16.06% 24.69B
-0.32%+12.96% - - 16.25B
+1.37%+14.53%+69.40%+135.94% 14.85B
+1.00%+9.67%+14.90%+21.88% 13.58B
+3.63%+9.53%+102.95%+104.79% 12.95B
Average +0.76%+7.09%+82.84%+106.27% 23.28B
Weighted average by Cap. +0.70%+7.52%+83.94%+133.04%

Financials

2024 2025
Net sales 528M 464M 428M 400M 750M 49.86B 766M 5.13B 1.99B 24.63B 1.98B 1.94B 85.44B 634M 557M 513M 481M 900M 59.86B 920M 6.16B 2.39B 29.56B 2.38B 2.33B 103B
Net income -56.11M -49.29M -45.42M -42.52M -79.61M -5.3B -81.35M -545M -211M -2.62B -211M -206M -9.07B -27.11M -23.82M -21.95M -20.55M -38.47M -2.56B -39.31M -263M -102M -1.26B -102M -99.57M -4.38B
Net Debt 194M 170M 157M 147M 275M 18.28B 281M 1.88B 729M 9.03B 727M 711M 31.33B 149M 131M 120M 113M 211M 14.05B 216M 1.45B 560M 6.94B 559M 547M 24.07B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock